Australian health authorities announced Wednesday that they received notice from Seqirus, the vaccine division of pharmaceutical company CSL, regarding plans to gradually halt production of Benpen injection medications for business-related reasons.
The medication contains benzylpenicillin sodium as its primary component, which serves as an injectable antibiotic commonly administered to prevent bacterial infections after surgical procedures and various other medical treatments.
The vaccine division informed Australia’s Therapeutic Goods Administration that the phase-out process will begin with the 600 milligrams strength variant starting November 30, 2026.
“The discontinuations are due to commercial decisions and are not related to product safety, quality or effectiveness,” the regulator added.
“Alternative Australian-registered benzylpenicillin sodium injection brands are expected to be available in the future.”
CSL did not immediately respond to a Reuters request for further details.
